Sorrento Therapeutics Announces Poster Presentations on its Anti-c-Met/PD-L1 Bispecific Antibodies and Anti-c-Met-Antibody Drug Conjugate at the 37th Annual San Antonio Breast Cancer Symposium

Dec 08, 2014, 09:15 ET from Sorrento Therapeutics, Inc.

SAN DIEGO, Dec. 8, 2014 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), a late-stage clinical oncology company developing new treatments for cancer and associated pain, announced today that it will present preclinical data on their bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs) against c-Met in breast cancer at the 37th Annual San Antonio Breast Cancer Symposium in San Antonio, Texas. Highlights of the findings include preclinical data on generation and evaluation of: i) anti-c-Met/anti-PD-L1 and anti-c-Met/anti-ErbB3 BsAbs, and ii) an anti-c-Met ADC as new immunotherapeutic strategies in breast cancer.

The findings will be presented by Dr. Kouros Motamed, Vice President of Strategic Alliances & Clinical Communications, on Thursday December 11th from 7:30-9:00 AM during the general poster session to be held at The Henry B. Gonzalez Convention Center, Exhibit Halls A-B.  The 2 presentations are entitled: "Bi-specific Antibodies Targeting Signaling Pathway Crosstalk are a New Breast Cancer Immunotherapeutic Strategy" (poster number P2-16-02), co-authored by Yanliang Zhang, Edwige Gros, Sarabjit Chagar, Heyue Zhou, John Dixon Gray, Jian Cao, Kimberly Johnson, Silpa Yalamanchili, Lisa Carmody, Bryan Jones, Kouros Motamed, Gunnar F. Kaufmann and Yanwen Fu and "c-Met is a Potential Therapeutic Target for Antibody Drug Conjugates in Breast Cancer" (poster number P2-16-03), authored by Yanwen Fu, Edwige Gros, Alice Lee, Kimberly Johnson, Hong Zhang, Silpa Yalamanchili, Yingqing Sun, Kouros Motamed, Gary Chen, Bryan Jones, Gunnar F. Kaufmann and David Miao.

About Sorrento Therapeutics, Inc. 

Sorrento is an oncology company developing new treatments for cancer and associated pain. Sorrento's most advanced asset Cynviloq™, the next-generation nanoparticle paclitaxel, commenced its registrational trial in March 2014 and is being developed under the abbreviated 505(b)(2) regulatory pathway. Sorrento is also developing RTX, a non-opiate TRPV1 agonist currently in a Phase 1/2 study at the NIH to treat terminal cancer patients suffering from intractable pain. The Company has made significant advances in developing human monoclonal antibodies, complemented by a comprehensive and fully integrated antibody drug conjugate (ADC) platform that includes proprietary conjugation chemistries, linkers, and toxic payloads. Sorrento's strategy is to enable a multi-pronged approach to combating cancer with small molecules, mono- and bi-specific therapeutic antibodies, and ADCs.

 

SOURCE Sorrento Therapeutics, Inc.



RELATED LINKS

http://www.sorrentotherapeutics.com
http://www.sorrentotherapeutics.com